AI and Real-time Monitoring Aid Process Operations

Published on: 

New technologies, such as artificial intelligence and machine learning, are being employed by bio/pharma manufacturers to collect and analyze large amounts of process data in real-time. An expert panel will discuss how this technology can be employed to optimize bio/pharma manufacturing and predictive maintenance during the Editors’ Series session, Technology Advances in Process Operations, part of the 2020 Bio/Pharma Virtual Congress on Nov. 11, 2020, 11:30 am EST.

The online Bio/Pharma Virtual Congress features panel discussions organized and moderated by the editors of Pharmaceutical Technology and BioPharm International magazines, sponsored technical sessions, a Virtual Exhibit Hall where visitors can chat in real-time with exhibitors, technical posters, and networking opportunities. Download the agenda (PDF).

This panel discussion will feature commentary from Bikash Chatterjee, CEO, Pharmatech Associates; Pamela Docherty, life sciences industry manager, Siemens; Amos Dor, general manager of the Pharma team, automation products group, Applied Materials; and Bob Lenich, global life sciences director, Emerson.

Additional manufacturing topics include process and operational intelligence through real-time visibility; process analytical technology to aid in process scale-up studies; and automated routine environmental monitoring and data integrity.

Registration for the day-long event (8:30 am–4 pm EST) is free to professionals involved in the development and manufacture of bio/pharmaceuticals.


Insight on the pandemic, bio/pharma’s response, and more

The COVID-19 pandemic’s impact on bio/pharmaceutical development and manufacturing, availability of crucial supplies, maintaining GMP compliance, and remote monitoring of manufacturing processes are other topics that will be discussed by industry experts during the 2020 Bio/Pharma Virtual Congress.

During a keynote panel discussion on Nov 11, 2020, 9 am EST, Bio/Pharma Industry—Beyond Politics and the Pandemic, representatives from industry organizations will discuss bio/pharma’s response to the pandemic and the corresponding scrutiny and political pressure, as well as the short-, medium-, and long-term implications for bio/pharma development and manufacturing.

Dosage Form Trends
How have biopharma companies responded and adjusted to pandemic issues? What lessons learned under fire may lead to more effective and efficient bioprocessing practices going forward? Eric Langer, managing partner, BioPlan Associates, Inc, shares research and expert insight in Delivering on the Promise: Overcoming Biopharma Development and Manufacturing Challenges, Drug Dosage Form track, Nov. 11, 2020, 10 am EST.

Formulation Trends
An expert panel will discuss the characterization of excipient components, understanding regulatory and compendial implications of excipient composition, the global supply chain, effective quality programs and prospects for preapproval of novel excipients. The Editors’ Series session, Excipients Update: Formulation, Supply and Quality, is scheduled for Nov. 11, 2020, 1:30 pm EST.

Bio/Pharma Industry Challenges
A panel discussion—A “New Normal” for Quality Practices—will reviewquality and regulatory challenges amid the pandemic, focusing on new technologies such as remote monitoring, risk-based quality management, Annex 1 changes, and lessons learned going forward. The panel, part of the Bio/Pharma Industry Challenges track, is scheduled for Nov. 11, 2020, 1:30 pm EST.

To learn more about the 2020 Bio/Pharma Virtual Congress, download the agenda (PDF).